PARTI I. Overview We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta (TGF) superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that l...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001104659-26-022551 | EDGAR | 102K words |
| 2025-02-27 | 2024-12-31 | 0001558370-25-001682 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001558370-24-003540 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0001558370-23-002992 | EDGAR | — |
| 2022-03-07 | 2021-12-31 | 0001558370-22-002928 | EDGAR | — |
| 2021-03-09 | 2020-12-31 | 0001558370-21-002641 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001558370-20-002536 | EDGAR | — |
| 2019-03-19 | 2018-12-31 | 0001558370-19-002252 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001104659-25-111935 | EDGAR | 59K words |
| 2025-08-06 | 2025-06-30 | 0001558370-25-010400 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007655 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001558370-24-015155 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011461 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-006908 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001558370-23-017854 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014293 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008674 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017598 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012641 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001558370-22-008975 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001104659-26-037350 | EDGAR | 1K words |
| 2026-03-03 | 0001104659-26-022547 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002757 | EDGAR | — |
| 2025-12-02 | 0001104659-25-117522 | EDGAR | — |
| 2025-11-14 | 0001104659-25-111956 | EDGAR | — |
| 2025-11-14 | 0001104659-25-111931 | EDGAR | — |
| 2025-10-14 | 0001104659-25-098894 | EDGAR | — |
| 2025-09-23 | 0001104659-25-092317 | EDGAR | — |
| 2025-08-06 | 0001558370-25-010399 | EDGAR | — |
| 2025-06-18 | 0001558370-25-008711 | EDGAR | — |
156 total filings indexed. 126 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001727196 |
| Ticker | SRRK |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.scholarrock.com |
| Listed | 2018-05-24 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report